Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about bluebird bio, Inc.
bluebird bio, Inc. News
Sep 5, 2025 - newsfilecorp.com
Mines d'Or Orbec Inc. Announces Shares for Debt Settlement
Aug 11, 2025 - newsfilecorp.com
Mines d'Or Orbec Appoints Jean-David Moore to Advisory Role
Jul 14, 2025 - newsfilecorp.com
Orbec Completes Over 2,000 Meters of Diamond Drilling on Its 100% Owned Muus Gold Property, Chibougamau, Quebec
Jul 8, 2025 - prnewswire.com
Brookdale's Board Reminds Shareholders to Vote the BLUE Proxy Card "FOR" ONLY Brookdale's Eight Superior and Highly Qualified Director Nominees Ahead of this Friday's Annual Meeting
bluebird bio, Inc. Quantitative Score
About bluebird bio, Inc.
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
bluebird bio, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
bluebird bio, Inc. Financials
Table Compare
Compare BLUE metrics with: | |||
|---|---|---|---|
Earnings & Growth | BLUE | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BLUE | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BLUE | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BLUE | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
bluebird bio, Inc. Income
bluebird bio, Inc. Balance Sheet
bluebird bio, Inc. Cash Flow
bluebird bio, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
bluebird bio, Inc. Executives
| Name | Role |
|---|---|
| Mr. Andrew Obenshain | President, Chief Executive Officer & Director |
| Dr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary |
| Mr. Thomas J. Klima | Chief Commercial & Operating Officer |
| Mr. Oliver James Sterling III | Chief Financial Officer & Principal Accounting Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Andrew Obenshain | President, Chief Executive Officer & Director | Male | 1975 | 746.61K |
| Dr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 1967 | 691.4K | |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | Male | 1972 | 574.49K |
| Mr. Thomas J. Klima | Chief Commercial & Operating Officer | Male | 1972 | 527.92K |
| Mr. Oliver James Sterling III | Chief Financial Officer & Principal Accounting Officer | Male | -- |
bluebird bio, Inc. Insider Trades
| Date | 30 May |
| Name | Vittiglio Joseph |
| Role | Chief Business & Legal Officer |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 1143 |
| Date | 2 Jun |
| Name | Vittiglio Joseph |
| Role | Chief Business & Legal Officer |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 2500 |
| Date | 2 Jun |
| Name | Vittiglio Joseph |
| Role | Chief Business & Legal Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 2500 |
| Date | 30 May |
| Name | Agwunobi John O |
| Role | Director |
| Transaction | Disposed |
| Type | U-Tender |
| Shares | 1323 |
| Date | 2 Jun |
| Name | Agwunobi John O |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 1245 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 30 May | Vittiglio Joseph | Chief Business & Legal Officer | Disposed | U-Tender | 1143 |
| 2 Jun | Vittiglio Joseph | Chief Business & Legal Officer | Disposed | D-Return | 2500 |
| 2 Jun | Vittiglio Joseph | Chief Business & Legal Officer | Acquired | A-Award | 2500 |
| 30 May | Agwunobi John O | Director | Disposed | U-Tender | 1323 |
| 2 Jun | Agwunobi John O | Director | Disposed | D-Return | 1245 |